CISBIO INTERNATIONAL : Cisbio International ajoute deux nouveaux produits à son portefeuille HTRF et accroît sa ligne de solutions de criblage à haut débit
Business Editors/Health/Medical Writers
BIOWIRE2K BAGNOLES-SUR-CEZE, France--(BUSINESS WIRE)--Aug 23, 2004--Cisbio international, spécialisée dans les technologies HTRF(R) et les services utilisés dans le criblage de médicaments et le développement de produits pour analyses, a annoncé la disponibilité de deux nouveaux produits pour le dosage de la kinase à utiliser dans les applications de criblage à haut débit.
Les nouveaux produits pour la kinase et l'ubiquitine couvriront une large gamme de cibles pour la kinase.
( BW)(MA-CISBIO-INTERNATIONAL) Cisbio International Adds to HTRF Portfolio With Introduction of Two Kinase Toolboxes; Company Expands Line of High-throughput Screening Solutions
Business Editors/Health/Medical Writers
BIOWIRE2K BAGNOLES-SUR-CEZE, France--(BUSINESS WIRE)--Aug 23, 2004--Cisbio international, an established developer of HTRF(R) technology and services used in assay development and drug screening, announced the availability of two novel kinase assay toolboxes for use in high-throughput applications.
The new kinase and ubiquitin toolboxes will cover a broad range of kinase targets.
Cisbio's kinase toolbox, which measure functional kinase activity, encompass the necessary technical requirements for the development of high throughput screening assays using the company's proprietary HTRF(R) technology.
HTRF(R) has established itself as a premier technology for kinase screening and all kinase assays use a flexible assay format allowing for standard miniaturization to 384 low volume or 1536 well formats.
The kinase toolbox consists of Eu3+-cryptate labeled antibodies for studying both serine/training and tyrosine kinases, including anti-phospho-serine/threoninne antibodies and anti-phospho tyrosine antibodies
"These two new toolboxes will allow our partners to streamline their assay development schedules when programming high throughput assays for identifying kinase targets," said Francois Degorce, head of HTRF marketing & business development, Cisbio international.
"When we developed these new assay tools, it was important that we deliver a system with a built-in flexibility for a each customer's assay optimization, as well as a strong screening component." Cisbio international's kinase toolboxes features homogeneous assays for the most popular targets in drug discovery, such as G-protein coupled receptors (GPCRs), kinases, and nuclear hormone receptors.
The assays are homogeneous, which greatly simplifies and speeds optimization for automation, as well as provides customers the flexibility to use a number of existing detection instruments already in their labs
The ubiquitin toolbox was designed to study the poly-ubiquitination pathway which is now acknowledged to be a significant degradation pathway for cellular proteins.
Ubiquitin is a protein whose main function is to mark other proteins for proteolysis (protein breakdown) as well as marking transmembrane proteins for removal from the membrane.
Both ubiquitin and the protein to be degraded are susceptible to recognition by specific enzymes that target poly-ubiquitination of the protein.
This mechanism was successfully demonstrated for the poly-ubiquitination of wild type p53 using cryptate-derivatized ubiquitin.
The assay has also been validated for use on select target proteins and on several ubiquitination related enzymes such as E2 and E3
European companies interested in receiving further information on Cisbio international's kinase toolboxes for assay development may call +33 (0)4 66 79 67 05.
US customers may call +1 800-221-7554
About Cisbio international
Cisbio international is an established developer of technologies that are used in assay development and drug screening procedures to enhance drug discovery.
The company is also a pioneer in the field of homogenous fluorescence methodologies via its proprietary technology, HTRF(R), and produces a selection of biological reagents and methods used by pharmaceutical and biotechnology companies, as well as CROs
For more information about Cisbio international and HTRF log onto www.htrf-assays.com
Editor's Note: In the expression "Eu3+" which appears in the second graph the "3+" is in superscript.
This may not appear correctly on all databases
CONTACT:
For Cisbio international
Paul Kidwell, 617-296-3854
paul_kidwell@hotmail.com
KEYWORD: MASSACHUSETTS FRANCE INTERNATIONAL EUROPE
INDUSTRY KEYWORD: PHARMACEUTICAL BIOTECHNOLOGY PRODUCT
SOURCE: Cisbio international